The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Request a free sample of this report:

“ Growing investor interest sparks more funding for psychedelic clinical trials ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ Growing investor interest sparks more funding for psychedelic clinical trials ”






      The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

      Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik